A proteomic approach combining MS and bioinformatic analysis for the detection and identification of biomarkers of administration of exogenous human growth hormone in humans

Proteomics - Clinical Applications

Volumn 3, Issue 8, 2009, Pages 912-922

  Boateng, Joshua ^a   Kay, Richard ^b   Lancashire, Lee ^a   Brown, Pamela ^b   Velloso, Cristina ^c   Bouloux, Pierre ^c   Teale, Phil ^b   Roberts, Jane ^b   Rees, Robert ^a   Ball, Graham ^a   Harridge, Stephen ^c   Goldspink, Geoffrey ^c   Creaser, Colin S ^d  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b Quotient Bioresearch Ltd   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d LOUGHBOROUGH UNIVERSITY   (United Kingdom)

Author keywords

Bioinformatics; ESI MS; LC; MALDI; MS; Serum biomarkers

Indexed keywords

ALPHA2 GLYCOPROTEIN; BIOLOGICAL MARKER; HUMAN GROWTH HORMONE; LEUCINE; PLACEBO; SOMATOMEDIN C;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; DATA BASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 70350233334     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800190     Document Type: Article

References (38)

1. Le Roith, D., Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N. Engl. J. Med. 1997, 336, 633-640.
2. Binder, G., Iliev, D. I., Mullis, P. E., Ranke, M. B., Catch-up growth in autosomal dominant isolated growth hormone deficiency (IGHD type II). Growth Horm. IGF Res. 2007, 17, 242-248.
3. Ehrnborg, C., Bengtsson, B. A., Rosen, T., Growth hormone abuse. Baillieres Best. Pract. Res. Clin. Endocrinol. Metab. 2000, 14, 71-77.
4. Rosen, T., Johannsson, G., Johansson, J. O., Bengtsson, B. A., Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper. Horm. Res. 1995, 43, 93-99.
5. Shin, N. K., Kim, D. Y., Shin, C. S., Hong, M. S. et al., High-level production of human growth hormone in Escherichia coli by a simple recombinant process. J. Biotechnol. 1998, 62, 143-151.
6. Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A. et al., Effects of human growth hormone in men over 60 years old. N. Engl. J. Med. 1990, 323, 1-6.
7. Rennie, M. J., Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes? Br. J. Sports Med. 2003, 37, 100-105.
8. Wallace, J. D., Cuneo, R. C., Bidlingmaier, M., Lundberg, P. A. et al., Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males. J. Clin. Endocrinol. Metab. 2001, 86, 1731-1737.
9. Hartman, M. L., Faria, A. C., Vance, M. L., Johnson, M. L. et al., Temporal structure of in vivo growth hormone secretory events in humans. Am. J. Physiol. 1991, 260, E101-E110.
10. Baumann, G., Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr. Rev. 1991, 12, 424-449.
11. De Palo, E. F., Gatti, R., Lancerin, F., Cappellin, E. et al., Correlations of growth hormone (GH) and insulin-like growth factor I (IGF-I): effects of exercise and abuse by athletes. Clin. Chim. Acta. 2001, 305, 1-17.
12. Barkan, A. L., Biochemical markers of acromegaly: GH vs. IGF-I. Growth Horm. IGF Res. 2004, 14, 97-1000.
13. Kniess, A., Ziegler, E., Kratzsch, J., Thieme, D. et al., Potential parameters for the detection of hGH doping. Anal. Bioanal. Chem. 2003, 376, 696-700.
14. Wallace, J. D., Cuneo, R. C., Baxter, R., Orskov, H. et al., Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adultmales: a potential test for GH abuse in sport. J. Clin. Endocrinol. Metab. 1999, 84, 3591-3601.
15. Kicman, A. T., Miell, J. P., Teale, J. D., Powrie, J. et al., Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. Clin. Endocrinol. (Oxf). 1997, 47, 43-50.
16. Healy, M. L., Dall, R., Gibney, J., Bassett, E. et al., Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting. J. Clin. Endocrinol. Metab. 2005, 90, 641-649.
17. Chace, D. H., Petricoin, E. F., Liotta, L. A., Mass spectrometry-based diagnostics: the upcoming revolution in disease detection has already arrived * Drs. Petricoin and Liotta respond. Clin. Chem. 2003, 49, 1227-1229.
18. Liotta, L. A., Petricoin, E. F., III, Ardekani, A. M., Hitt, B. A. et al., General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol. Oncol. 2003, 88, 25-28.
19. Mian, S., Ugurel, S., Parkinson, E., Schlenzka, I. et al., Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 2005, 23, 5088-5093.
20. Ball, G., Mian, S., Holding, F., Allibone, R. O. et al., An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 2002, 18, 395-404.
21. Lancashire, L., Mian, S., Ellis, I., Rees, R. et al., Current developments in the analysis of proteomic data: artificial neural network data mining techniques for the identification of proteomic biomarkers related to breast cancer. Curr. Proteomics 2005, 2, 15-29.
22. Boateng, J., Lancashire, L., Brown, P., Ahmed, M. et al., The use of proteomic and bioinformatics techniques for the detection of protein biomarkers following growth hormone administration. The Internet J. Genomics Proteomics 2007, 2.
23. Chung, L., Clifford, D., Buckley, M., Baxter, R. C., Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J.Clin. Endocrinol. Metab. 2006, 91, 671-677.
24. Aphergis, M., Velloso, C., Hameed, M., Brothwood, T. et al., Serum IGF-I levels and IGF-I gene splicing in muscle of healthy young males receiving rhGH. Growth Horm. IGF Res. 2008, doi:10.1016/ j.ghir.2008.07.002.
25. Matharoo-Ball, B., Ratcliffe, R., Lancashire, L., Ugurel, S. et al., Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach. Proteomics - Clin. Appl. 2007, 1, 605-620.
26. Kay, R. G., Barton, C., Ratcliffe, L., Matharoo-Ball, B. et al., Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry-based proteomic analysis. Rapid Commun. Mass Spectrom. 2008, 22, 3255-3260.
27. Erotokritou-Mulligan, I., Bassett, E. E., Kniess, A., Sönksen, P. H. et al., Validation of the growth hormone (GH)-dependent marker method of detecting GH abuse in sport through the use of independent data sets. Growth. Horm. IGF Res. 2007, 17, 416-423.
28. Michiels, S., Koscielny, S., Hill, C., Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005, 365, 488-492.
29. Iversen, C., Lancashire, L., Waddington, M., Forsythe, S. et al., Identification of Enterobacter sakazakii from closely related species: the use of artificial neural networks in the analysis of biochemical and 16S rDNA data. BMC Microbiol. 2006, 13, 6-28.
30. Berg, M., Parbel, A., Pettersen, H., Fenyo, D., Bjorkesten, L., Detection of artifacts and peptide modifications in liquid chromatography/mass spectrometry data using twodimensional signal intensity map data visualization. Rapid Commun. Mass Spectrom. 2006, 20, 1558-1562.
31. Takahashi, N., Takahashi, Y., Putnam, F. W., Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum. Proc. Natl. Acad. Sci. USA 1985, 82, 1906-1910.
32. Heo, S. H., Lee, S. J., Ryoo, H. M., Park, J. Y. et al., Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 2007, 7, 4292-4302.
33. Okano, T., Kondo, T., Kakisaka, T., Fujii, K. et al., Plasma proteomics of lung cancer by a linkage ofmulti-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6, 3938-3948.
34. Kakisaka, T., Kondo, T., Okano, T., Fujii, K. et al., Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucinerich alpha-2-glycoprotein in pancreatic cancer. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852, 257-267.
35. Kawakami, T., Hoshida, Y., Kanai, F., Tanaka, Y. et al., Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 2005, 5, 4287-4295.
36. Holly, J. M., Gunnell, D. J., Davey Smith, G., Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J. Endocrinol. 1999, 162, 321-330.
37. Kay, R. G., Gregory, B., Grace, P. B., Pleasance, S., The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun. Mass Spectrom. 2007, 21, 2585-2593.
38. Weivoda, S., Andersen, J. D., Skogen, A., Schlievert, P. M. et al., ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. J. Immunol. Methods 2008, 336, 22-29.